INDSWFTLAB379.00

Ind-Swift Laboratories Limited

· Pharma & Health
₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,291 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity45.2521.352.992.99
Return on Assets36.1717.412.472.47
Return on Capital Employed21.29-3.601.021.02
Return on Invested Capital28.80-5.711.272.47
Margins
EBITDA Margin19.85-3.457.038.97
Operating Margin15.68-7.812.262.26
Incremental Operating Margin34.0373.33
Pretax Margin45.4245.907.6510.72
Net Income Margin32.9044.596.468.62
FCF Margin-17.60-16.00-23.53-23.53
Additional
Effective Tax Rate26.002.8215.7615.64
Sustainable Growth Rate45.2521.352.992.99
Incremental Operating Margin %34.0373.3358.23
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.